Your search for dabigatran returned 118 results

Findings may help with decision-making in this high-risk patient population.

The summary below gives an overview of some of the important additions and changes MPR has made to its drug database through the end of January. The chart below provides highlights of the 118 key monograph updates made this month (not an inclusive list).

Boehringer Ingelheim announced that the Pradaxa (dabigatran etexilate mesylate capsules) prescribing information has been updated to affirm that Pradaxa 150mg twice daily was superior in reducing ischemic and hemorrhagic strokes relative to warfarin

The FDA has notified healthcare professionals that it is evaluating post-marketing reports of serious bleeding events in patients taking Pradaxa (dabigatran etexilate mesylate; Boehringer Ingelheim).

Idarucizumab (Praxbind) was recently granted accelerated approval as a reversal agent for patients on Pradaxa during emergency situations.

Treatment visits for use of anticoagulants are on an upward trend and driven largely by the popularity of new direct oral anticoagulants, which tripled in use from 2013-2014.

Most people with nonvalvular atrial fibrillation (NVAF) should be taking oral anticoagulants to prevent stroke.

The summary below gives an overview of some of the important additions and changes MPR has made to its drug database through the end of February. The chart below provides highlights of the 118 key monograph updates made this month (not an inclusive list).

Three major updates were added to the prescribing information for Pradaxa capsules, an oral anticoagulant. One included a warning that discontinuing treatment puts patients at increased risk of stroke.

Boehringer Ingelheim announced that it is conducting a nationwide recall of a single manufacturing lot of Pradaxa (dabigatran etexilate mesylate) capsules 75mg.